Mealey's (June 1, 2016, 1:32 PM EDT) -- ALEXANDRIA, Va. — A claimed method and composition for treating cancer with hormone therapy is likely unpatentable under 35 U.S. Code Section 103, the Patent Trial and Appeal Board ruled May 31 in a decision granting inter partes review (Amerigen Pharmaceuticals Ltd. v. Janssen Oncology Inc., No. IPR2016-00286, PTAB)....